IP Library Granted Patent US 8,299,024
Granted Patent B2
US 8,299,024 · App. 12/298,933 · Granted Oct 30, 2012

Methods to restore glycemic control

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,299,024
App. No.
12/298,933
Granted
Oct 30, 2012
Kind
B2
Abstract

Provided herein are methods and compositions to achieve a sustained delay in the progression of, or an amelioration of diabetes in a subject, or a delay in diabetes onset in a subject at risk for diabetes, comprising an abbreviated course of administration of a pharmaceutical composition comprising an exendin or an exendin agonist analog in an amount effective to induce cell regeneration.

Claims (5)

1. A method to achieve sustained normoglycemia in a human with diabetes comprising administering to said human a pharmaceutical composition comprising a peptide selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, and SEQ ID NO: 12 for a period of time and in an amount effective to achieve normoglycemia in the human and then ceasing said administering for at least one week, whereby normoglycemia is sustained for said at least one week.

2. The method of claim 1 wherein the peptide is SEQ ID NO: 1.

3. The method of claim 1 wherein the peptide is SEQ ID NO: 2.

4. The method of claim 1 wherein the peptide is SEQ ID NO: 3.

5. The method of claim 1 wherein the peptide is SEQ ID NO: 12.

Assignments (2)
RELEASE OF SECURITY INTEREST Recorded Oct 2, 2012
From: ELI LILLY AND COMPANY
To: AMYLIN PHARMACEUTICALS, INC.
Reel/Frame 029062/0639 →
SECURITY AGREEMENT Recorded Nov 8, 2011
From: AMYLIN PHARMACEUTICALS, INC.
To: ELI LILLY AND COMPANY
Reel/Frame 027192/0334 →